Comparative Pharmacology
Head-to-head clinical analysis: ACTICLATE CAP versus SEYSARA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTICLATE CAP versus SEYSARA.
ACTICLATE CAP vs SEYSARA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding.
Sarecycline is a tetracycline-class antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the addition of amino acids to the growing peptide chain. It also has anti-inflammatory properties through inhibition of neutrophil chemotaxis and reduction of pro-inflammatory cytokines.
350 mg orally once daily, increased to 350 mg twice daily if no response after 2 weeks.
100 mg orally once daily with food.
None Documented
None Documented
Terminal elimination half-life 6-10 hours; prolonged in renal impairment (up to 22 hours in anuria)
The terminal elimination half-life after oral administration is approximately 12 hours (range 10-14 hours), supporting once-daily dosing.
Renal (60-70% as unchanged drug), fecal (20-30% as metabolites); minor biliary elimination
Renal excretion of unchanged drug accounts for approximately 66% of the administered dose; fecal elimination is about 33%.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic